Entrada Therapeutics (TRDA) News Today $12.69 +0.15 (+1.20%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Barclays PLC Buys 30,585 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)Barclays PLC grew its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 210.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,110 shares of the company's stock after acquiring an additionJanuary 16, 2025 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Trading Down 7.6% - Here's WhyEntrada Therapeutics (NASDAQ:TRDA) Trading Down 7.6% - Time to Sell?January 10, 2025 | marketbeat.comGeode Capital Management LLC Has $9.21 Million Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Geode Capital Management LLC boosted its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 8.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 576,451 shares of the company's stock after buying an additional 46,512 shares duriJanuary 2, 2025 | marketbeat.comBarclays PLC Increases Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Barclays PLC lifted its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 210.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,110 shares of the company's stock after acquiring an additJanuary 1, 2025 | marketbeat.comEntrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2024 | globenewswire.comInsider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 22,935 Shares of StockDecember 13, 2024 | insidertrades.comXTX Topco Ltd Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA)XTX Topco Ltd bought a new position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 39,670 shares of the company's stock, valued at approximatelyDecember 13, 2024 | marketbeat.comFmr LLC Sells 85,667 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)Fmr LLC reduced its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 4.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,743,498 shares of the company's stock after sellingDecember 10, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $3.23 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Jacobs Levy Equity Management Inc. boosted its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 50.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 201,803 shares of the company's stock aDecember 7, 2024 | marketbeat.comJanus Henderson Group PLC Has $27.36 Million Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Janus Henderson Group PLC grew its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 10.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,711,459 shares of the company's stock after purchaDecember 7, 2024 | marketbeat.comRoth MKM Initiates Coverage of Entrada Therapeutics (TRDA) with Buy RecommendationDecember 6, 2024 | msn.comEntrada Therapeutics (NASDAQ:TRDA) Now Covered by Analysts at Roth MkmRoth Mkm initiated coverage on shares of Entrada Therapeutics in a research note on Thursday. They issued a "buy" rating and a $29.00 price objective on the stock.December 6, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth Sells 1,000 SharesDecember 4, 2024 | insidertrades.comMassachusetts Financial Services Co. MA Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Massachusetts Financial Services Co. MA acquired a new stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 69,394 shares of the company's stock, valued at appNovember 28, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $2.22 Million Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 132.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,605 shares of tNovember 26, 2024 | marketbeat.comLos Angeles Capital Management LLC Purchases Shares of 33,932 Entrada Therapeutics, Inc. (NASDAQ:TRDA)Los Angeles Capital Management LLC acquired a new stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 33,932 shares of the company's stock, vaNovember 17, 2024 | marketbeat.comNatarajan Sethuraman Sells 1,409 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockNovember 14, 2024 | insidertrades.comQ4 EPS Estimate for Entrada Therapeutics Lifted by AnalystEntrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Stock analysts at HC Wainwright boosted their Q4 2024 earnings per share (EPS) estimates for Entrada Therapeutics in a research report issued on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company wiNovember 8, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for TRDA FY2024 Earnings?Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of Entrada Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now forecastNovember 7, 2024 | marketbeat.comFY2024 Earnings Forecast for TRDA Issued By William BlairEntrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Research analysts at William Blair raised their FY2024 EPS estimates for Entrada Therapeutics in a report released on Tuesday, November 5th. William Blair analyst M. Minter now expects that the company will post earnings per share of $1.19November 7, 2024 | marketbeat.comEntrada Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 7, 2024 | finance.yahoo.comEntrada Therapeutics: Strong Buy Recommendation Backed by Promising Clinical Progress and Robust Financial HealthNovember 7, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)November 7, 2024 | markets.businessinsider.comOppenheimer Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock PriceOppenheimer boosted their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the company an "outperform" rating in a research report on Wednesday.November 6, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Price Target Raised to $20.00HC Wainwright boosted their target price on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday.November 6, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Hits New 12-Month High - Here's What HappenedEntrada Therapeutics (NASDAQ:TRDA) Hits New 12-Month High - What's Next?November 5, 2024 | marketbeat.comEntrada Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 5, 2024 | markets.businessinsider.comShort Interest in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Declines By 19.1%Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 1,650,000 shares, a decline of 19.1% from the September 30th total of 2,040,000 shares. Currently, 7.6% of the shares of the company are short sold. Based on an average daily trading volume, of 139,800 shares, the short-interest ratio is currently 11.8 days.October 28, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Natarajan Sethuraman Sells 600 SharesOctober 19, 2024 | insidertrades.comNatarajan Sethuraman Sells 600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) insider Natarajan Sethuraman sold 600 shares of the company's stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $18.00, for a total value of $10,800.00. Following the completion of the sale, the insider now owns 183,216 shares of the company's stock, valued at $3,297,888. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.October 18, 2024 | marketbeat.comHere's What Could Help Entrada Therapeutics (TRDA) Maintain Its Recent Price StrengthOctober 15, 2024 | finance.yahoo.comRenaissance Technologies LLC Takes $636,000 Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Renaissance Technologies LLC bought a new position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 44,600 shares of the company's stock, valued at approximateOctober 10, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comEntrada Therapeutics Presents Data Supporting Advancement Of Duchenne FranchiseOctober 9, 2024 | markets.businessinsider.comEntrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle SocietyOctober 9, 2024 | globenewswire.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) COO Sells $13,552.00 in StockOctober 1, 2024 | insidertrades.comEntrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and DevelopmentSeptember 24, 2024 | globenewswire.comEntrada Therapeutics (NASDAQ:TRDA) Trading Up 6.7%Entrada Therapeutics (NASDAQ:TRDA) Shares Up 6.7%September 19, 2024 | marketbeat.comāshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of DirectorsSeptember 17, 2024 | finance.yahoo.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan J. Dowden Sells 1,904 SharesSeptember 11, 2024 | insidertrades.comNatarajan Sethuraman Sells 2,642 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockSeptember 11, 2024 | insidertrades.comEntrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant ProgramSeptember 6, 2024 | globenewswire.comEntrada Therapeutics (NASDAQ:TRDA) Stock Price Down 11.2%Entrada Therapeutics (NASDAQ:TRDA) Stock Price Down 11.2%September 3, 2024 | marketbeat.comEntrada Therapeutics Inc (TRDA) Gets a Buy from OppenheimerAugust 27, 2024 | markets.businessinsider.comEntrada Therapeutics' (TRDA) "Outperform" Rating Reaffirmed at OppenheimerOppenheimer reaffirmed an "outperform" rating and set a $25.00 target price on shares of Entrada Therapeutics in a research report on Monday.August 26, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Stock Price Down 3%Entrada Therapeutics (NASDAQ:TRDA) Trading Down 3%August 21, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Sees Large Volume IncreaseEntrada Therapeutics (NASDAQ:TRDA) Sees Unusually-High Trading VolumeAugust 19, 2024 | marketbeat.comForecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved DrasticallyAugust 18, 2024 | finance.yahoo.comEntrada Therapeutics (NASDAQ:TRDA) Releases Quarterly Earnings Results, Beats Estimates By $0.90 EPSEntrada Therapeutics (NASDAQ:TRDA - Get Free Report) released its quarterly earnings results on Tuesday. The company reported $1.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.90. The business had revenue of $94.69 million during the quarter, compared to the consensus estimate of $55.00 million. Entrada Therapeutics had a return on equity of 9.73% and a net margin of 14.42%.August 15, 2024 | marketbeat.comEntrada Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 14, 2024 | finance.yahoo.com Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address TRDA Media Mentions By Week TRDA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRDA News Sentiment▼1.670.44▲Average Medical News Sentiment TRDA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRDA Articles This Week▼12▲TRDA Articles Average Week Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IDEAYA Biosciences News Mesoblast News Agios Pharmaceuticals News Apogee Therapeutics News Amphastar Pharmaceuticals News Tarsus Pharmaceuticals News Iovance Biotherapeutics News Disc Medicine News ImmunityBio News Wave Life Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRDA) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
